Who are GSK573719/VI 125/25's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): umeclidinium bromide and vilanterol trifenatate, GSK573719/GW642444 Inhalation Powder.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/gsk573719-vi-125-25.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

GSK573719/VI 125/25 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

GSK573719/VI 125/25 (GSK573719/VI 125/25) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: LAMA/LABA combination (long-acting muscarinic antagonist/long-acting beta-2 agonist). Area: Respiratory/Pulmonology.

phase 3 LAMA/LABA combination (long-acting muscarinic antagonist/long-acting beta-2 agonist) M3 muscarinic receptor and beta-2 adrenergic receptor Respiratory/Pulmonology Small molecule Live · refreshed every 30 min

Target snapshot

GSK573719/VI 125/25 (GSK573719/VI 125/25) — GlaxoSmithKline. GSK573719/VI 125/25 is a combination of an inhaled long-acting muscarinic antagonist (LAMA) and long-acting beta-2 agonist (LABA) that relaxes airway smooth muscle and improves airflow in chronic obstructive pulmonary disease.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
GSK573719/VI 125/25 TARGET	GSK573719/VI 125/25	GlaxoSmithKline	phase 3	LAMA/LABA combination (long-acting muscarinic antagonist/long-acting beta-2 agonist)	M3 muscarinic receptor and beta-2 adrenergic receptor
umeclidinium bromide and vilanterol trifenatate	umeclidinium bromide and vilanterol trifenatate	Chiesi Farmaceutici S.p.A.	marketed	Long-acting muscarinic antagonist / Long-acting beta-2 agonist combination (LAMA/LABA)	M3 muscarinic receptor and beta-2 adrenergic receptor
GSK573719/GW642444 Inhalation Powder	GSK573719/GW642444 Inhalation Powder	GlaxoSmithKline	phase 3	LAMA/LABA combination (long-acting muscarinic antagonist/long-acting beta-2 agonist)	M3 muscarinic receptor; beta-2 adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (LAMA/LABA combination (long-acting muscarinic antagonist/long-acting beta-2 agonist) class)

GlaxoSmithKline · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). GSK573719/VI 125/25 — Competitive Intelligence Brief. https://druglandscape.com/ci/gsk573719-vi-125-25. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab